Help appealing denials for this endothelin receptor antagonist for IgA nephropathy.

Appeal Your Vanrafia Denial

Get access to this treatment for reducing proteinuria in IgA nephropathy.

Start Your Appeal
Chat with AI Assistant

Understanding Your Vanrafia (atrasentan) Denial

Vanrafia (atrasentan) is an endothelin receptor antagonist approved for reducing proteinuria in adults with primary IgA nephropathy at risk for disease progression. Reducing proteinuria is critical for slowing kidney disease. Insurance often requires documentation of biopsy-proven diagnosis and prior treatment with ACE inhibitors or ARBs.

Common Reasons for Denial

  • ! Prior authorization required
  • ! Biopsy-proven IgAN not documented
  • ! Proteinuria level not high enough
  • ! Must be on maximum ACEi/ARB therapy
  • ! Specialty tier drug not covered
  • ! New drug with limited coverage policies

How We Help

We help you document your kidney biopsy results, proteinuria levels, eGFR, current ACE inhibitor/ARB therapy, and risk factors for disease progression.

Start your Vanrafia appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Atrasentan is a selective endothelin A receptor antagonist that reduces proteinuria in IgA nephropathy.

✓ Clinical trials demonstrated significant reduction in proteinuria compared to placebo.

✓ Reducing proteinuria is associated with slower progression to kidney failure in IgA nephropathy.

✓ Endothelin pathway blockade provides a complementary mechanism to renin-angiotensin system inhibition.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

Travere Therapeutics Patient Support ↗

Patient support program offering access and affordability assistance for eligible patients.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

IgA Nephropathy Foundation of America ↗

Foundation dedicated to IgA nephropathy awareness, research, and patient support.

National Kidney Foundation ↗

Leading kidney health organization with advocacy and patient resources.

Frequently Asked Questions

Include kidney biopsy confirming IgA nephropathy, urine protein levels showing significant proteinuria (typically 1 g/day or higher), eGFR results, and documentation that you're on maximally tolerated ACE inhibitor or ARB therapy.

Yes, Vanrafia is typically used in addition to supportive care with ACE inhibitors or ARBs. Discuss with your nephrologist how it fits with your overall treatment plan.

Vanrafia blocks the endothelin A receptor, reducing inflammation and scarring in the kidneys and decreasing protein leakage into the urine.

Ready to Fight Your Vanrafia (atrasentan) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Travere Therapeutics. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.